HC Wainwright & Co. analyst Andrew Fein reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.
Indus Raises Quarterly Dividend From $0.16/Share To $0.18/Share
INDUS Realty Trust, Inc. (NASDAQ:INDT) ("INDUS" or the "Company") a U.S.-based industrial/logistics REIT, announced that its Board of Directors has declared a cash dividend of $0.18 per